New pill aims to tackle heart failure and obesity together
NCT ID NCT06820099
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called HRS-7535 in 225 adults who have both heart failure (with mildly reduced or preserved pumping ability) and obesity. Participants will receive either the drug or a placebo for 36 weeks to see if it helps with weight loss and reduces inflammation. The goal is to find a new treatment option that manages both conditions at once.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULTS WITH HEART FAILURE, MILD DECREASE IN EJECTION FRACTION/PRESERVED EJECTION FRACTION, AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fuwai Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?